Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.

CONTEXT Rapid time to treatment with thrombolytic therapy is associated with lower mortality in patients with acute myocardial infarction (MI). However, data on time to primary angioplasty and its relationship to mortality are inconclusive. OBJECTIVE To test the hypothesis that more rapid time to reperfusion results in lower mortality in the strategy of primary angioplasty. DESIGN Prospective observational study of data collected from the Second National Registry of Myocardial Infarction between June 1994 and March 1998. SETTING A total of 661 community and tertiary care hospitals in the United States. SUBJECTS A cohort of 27,080 consecutive patients with acute MI associated with ST-segment elevation or left bundle-branch block who were treated with primary angioplasty. MAIN OUTCOME MEASURE In-hospital mortality, compared by time from acute MI symptom onset to first balloon inflation and by time from hospital arrival to first balloon inflation (door-to-balloon time). RESULTS Using a multivariate logistic regression model, the adjusted odds of in-hospital mortality did not increase significantly with increasing delay from MI symptom onset to first balloon inflation. However, for door-to-balloon time (median time 1 hour 56 minutes), the adjusted odds of mortality were significantly increased by 41% to 62% for patients with door-to-balloon times longer than 2 hours (for 121-150 minutes: odds ratio [OR], 1.41; 95% confidence interval [CI], 1.08-1.84; P=.01; for 151-180 minutes: OR, 1.62; 95% CI, 1.23-2.14; P<.001; and for >180 minutes: OR, 1.61; 95% CI, 1.25-2.08; P<.001). CONCLUSIONS The relationship in our study between increased mortality and delay in door-to-balloon time longer than 2 hours (present in nearly 50% of this cohort) suggests that physicians and health care systems should work to minimize door-to-balloon times and that door-to-balloon time should be considered when choosing a reperfusion strategy. Door-to-balloon time also appears to be a valid quality-of-care indicator. JAMA. 2000.

[1]  B. Brodie,et al.  Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. , 2000, Circulation.

[2]  S. Greenhouse,et al.  A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial , 1999 .

[3]  T. Ryan,et al.  The relationship between operator volume and outcomes after percutaneous coronary interventions in high volume hospitals in 1994-1996: the northern New England experience. Northern New England Cardiovascular Disease Study Group. , 1999, Journal of the American College of Cardiology.

[4]  J S Alpert,et al.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.

[5]  P. Rosenbaum,et al.  Invited commentary: propensity scores. , 1999, American journal of epidemiology.

[6]  N. Every,et al.  A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project. , 1999, Journal of the American College of Cardiology.

[7]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[8]  NicolasDanchin,et al.  Treatment of Acute Myocardial Infarction by Primary Coronary Angioplasty or Intravenous Thrombolysis in the “Real World” , 1999 .

[9]  J. Ferrières,et al.  Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey. , 1999, Circulation.

[10]  H. Olsson,et al.  Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. , 1999, Journal of the American College of Cardiology.

[11]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[12]  C. Cannon.  Timely thrombolysis: synergism to open arteries and reduce mortality rates. , 1999, American heart journal.

[13]  B. Brodie,et al.  Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. , 1998, Journal of the American College of Cardiology.

[14]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[15]  A. Kastrati,et al.  Operator volume and outcome of patients undergoing coronary stent placement. , 1998, Journal of the American College of Cardiology.

[16]  J. Gurwitz,et al.  Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). , 1998, The American journal of cardiology.

[17]  R. O’Connor,et al.  Dangers of delay of initiation of either thrombolysis or primary angioplasty in acute myocardial infarction with increasing use of primary angioplasty. , 1998, The American journal of cardiology.

[18]  J. Gore,et al.  Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). , 1998, Journal of the American College of Cardiology.

[19]  G. Stone,et al.  Safety and Cost-Effectiveness of Early Discharge After Primary Angioplasty in Low Risk Patients With Acute Myocardial Infarction 11Research funding for this study was provided by unrestricted grants from Advanced Cardiovascular Systems, Santa Clara, California; Mallinckrodt Medical, Inc., Saint Loui , 1998 .

[20]  T. Ryan,et al.  Operator volume and outcomes in 12,998 percutaneous coronary interventions. Northern New England Cardiovascular Disease Study Group. , 1998, Journal of the American College of Cardiology.

[21]  R. Gibbons,et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. , 1998, JAMA.

[22]  R. Gibbons,et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction : A quantitative review , 1997 .

[23]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[24]  M. Simoons,et al.  A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. , 1997, The New England journal of medicine.

[25]  E. DeLong,et al.  Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients. , 1997, Circulation.

[26]  A. Berman,et al.  Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. , 1997, American Journal of Cardiology.

[27]  K. Beatt,et al.  A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. , 1997, The New England journal of medicine.

[28]  E L Hannan,et al.  Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. , 1997, JAMA.

[29]  R. Schiele,et al.  Primary Angioplasty Versus Thrombolysis in the Treatment of Acute Myocardial Infarction , 1997 .

[30]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[31]  J S Martin,et al.  A Comparison of Thrombolytic Therapy with Primary Coronary Angioplasty for Acute Myocardial Infarction , 1996 .

[32]  J. Muhlestein,et al.  Explaining discrepant mortality results between primary percutaneous transluminal coronary angioplasty and thrombolysis for acute myocardial infarction. , 1996, American Journal of Cardiology.

[33]  F Van de Werf,et al.  Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. , 1996, Journal of the American College of Cardiology.

[34]  J. Hirst,et al.  Angiographic complications of primary angioplasty , 1996 .

[35]  S. Kimmel,et al.  The relationship between coronary angioplasty procedure volume and major complications. , 1995, JAMA.

[36]  H. Krumholz,et al.  Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. , 1995, JAMA.

[37]  E. Antman,et al.  755-2 Current Management of ST Elevation Myocardial Infarction and Outcome of Thrombolytic Ineligible Patients: Results of the Multicenter TIMI 9 Registry , 1995 .

[38]  D. Pryor,et al.  The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality. , 1994, The New England journal of medicine.

[39]  C. Cannon,et al.  Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.

[40]  W. Rogers,et al.  Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators. , 1994, The American journal of cardiology.

[41]  E. Braunwald,et al.  GUSTO, TIMI and the case for rapid reperfusion. , 1994, Acta cardiologica.

[42]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[43]  E. Braunwald.  The open-artery theory is alive and well--again. , 1993, The New England journal of medicine.

[44]  J. Reiber,et al.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. , 1993, The New England journal of medicine.

[45]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .

[46]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[47]  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[48]  Mervyn G. Marasinghe,et al.  SAS System for Linear Models , 1991 .

[49]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[50]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[51]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[52]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[53]  J. Lowe,et al.  The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.

[54]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[55]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.